Document:

EX-10.4

 Exhibit 10.4 

COMPANY HOLDERS SUPPORT AGREEMENT 

This Company Holders Support Agreement (this “Agreement”), dated as of October 6, 2021, is entered into by and among
Supernova Partners Acquisition Company II, Ltd., a Cayman Islands exempted company which shall domesticate as a Delaware corporation prior to the Closing in accordance with the Merger Agreement (such entity, including the continuing corporation,
“Acquiror”), Rigetti Holdings, Inc., a Delaware corporation (the “Company”), and certain of the stockholders of the Company, whose names appear on the signature pages of this Agreement (such
stockholders, the “Stockholders”, and Acquiror, the Company and the Stockholders, each a “Party”, and collectively, the “Parties”). 

RECITALS 
 WHEREAS,
concurrently herewith, Acquiror, Supernova Merger Sub, Inc., a Delaware corporation (“First Merger Sub”), Supernova Romeo Merger Sub, LLC, a Delaware limited liability company (“Second Merger Sub” and,
together with First Merger Sub, “Merger Subs” and each, a “Merger Sub”), and the Company, are entering into an Agreement and Plan of Merger (as amended, supplemented, restated or otherwise modified
from time to time, the “Merger Agreement”; capitalized terms used but not otherwise defined in this Agreement shall have the meanings ascribed to them in the Merger Agreement), pursuant to which, among other transactions,
(i) Acquiror will domesticate as a Delaware corporation, (ii) First Merger Sub will merge with and into the Company (the “First Merger”), with the Company surviving such First Merger as a wholly owned subsidiary of
Acquiror, and (iii) immediately following the First Merger and as part of the same overall transaction as the First Merger, the Company will merge with and into Second Merger Sub (the “Second Merger” and, together with
the First Merger, the “Mergers”), with the Second Merger Sub surviving such Second Merger as a wholly owned subsidiary of Acquiror, subject to the terms and conditions set forth therein; 

WHEREAS, as of the date hereof, each Stockholder is the sole record owner and “beneficial owner” (as such term is used
herein, within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (together with the rules and regulations promulgated thereunder, the “Exchange Act”)) of,
and has the sole power to dispose of and vote (or direct the voting of), the number, class and series of shares of Company Stock set forth opposite such Stockholder’s name on Schedule 1 attached hereto (such shares, together with
(1) any shares of Company Stock (or any securities convertible into or exercisable or exchangeable for Company Stock) of which such Stockholder has record or beneficial ownership as of the date hereof and that are not reflected on Schedule
1, (2) any additional shares of Company Stock (or any securities convertible into or exercisable or exchangeable for shares of Company Stock) of which such Stockholder acquires record or beneficial ownership after the date hereof, including by
Transfer (as defined below), purchase, as a result of a stock dividend, stock split, recapitalization, combination, reclassification, exchange or change of such shares, or upon exercise or conversion of any securities, and (3) any additional
shares of Company Stock with respect to which such Stockholder has the right to vote through a proxy or otherwise, such Stockholder’s “Covered Shares”); 

 WHEREAS, the Stockholders agree to take all action necessary to terminate, subject to
and effective immediately prior to the Closing, each of the following agreements (to the extent the Stockholder is party thereto): (i) that certain Amended and Restated Investors’ Rights Agreement, dated as of February 18, 2020, by and
among the Company as assignee of Rigetti & Co, Inc., a Delaware corporation (“Rigetti”), the Investors and the Key Holders (each as defined therein); (ii) that certain Amended and Restated Voting Agreement, dated as
of February 18, 2020, by and among the Company as assignee of Rigetti, the Investors and the Common Holders (each as defined therein); (iii) that certain Amended and Restated Right of First Refusal and
Co-Sale Agreement, dated as of February 18, 2020, by and among the Company as assignee of Rigetti, the Investors, the Legacy Converted Investors and the Common Holders (each as defined therein); and
(iv) each of the other investment agreements identified on Section 5.25 of the Company Disclosure Letter (such agreements described in clauses (i)-(iv), collectively, the “Investment Agreements”); and 

WHEREAS, as a condition and inducement to the willingness of Acquiror to enter into the Merger Agreement, the Company and the
Stockholders are entering into this Agreement. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally
bound hereby, Acquiror, the Company and each Stockholder hereby agree as follows: 
 1. Agreement to Vote. Prior to the Termination
Date (as defined below), each Stockholder, solely in his, her or its capacity as a stockholder or proxy holder of the Company, irrevocably and unconditionally agrees to validly execute and deliver to the Company in respect of all of the
Stockholder’s Covered Shares entitled to vote or consent on matters put to a vote or consent, as applicable, of the Company’s stockholders (such Covered Shares, each Stockholder’s “Voting Covered Shares”), as
soon as reasonably practicable after the Registration Statement is declared effective under the Securities Act, and in any event within forty-eight (48) hours thereafter, a written consent in respect of all of the Stockholder’s Voting
Covered Shares approving the Merger Agreement and the Transactions. In addition, prior to the Termination Date, each Stockholder, in his, her or its capacity as a stockholder or proxy holder of the Company, irrevocably and unconditionally agrees
that (i) it shall, and shall cause each other holder of record of any of such Stockholder’s Voting Covered Shares to, take any and all actions necessary or reasonably requested by Acquiror or the Company in order to effect the conversion,
effective as of immediately prior to and conditioned upon the Closing, of all of the outstanding shares of Company Preferred Stock into Company Common Stock pursuant to the terms of the Governing Documents of the Company, including, without
limitation, approval, execution and delivery of a written request for such conversion pursuant to Section 4(b) of Article V thereof, and (ii) at any meeting of the stockholders of the Company (whether annual or special and whether or not
an adjourned or postponed meeting, however called and including any adjournment or postponement thereof) and in connection with any written consent of stockholders of the Company, such Stockholder shall, and shall cause each other holder of record
of any of such Stockholder’s Voting Covered Shares to: 
 (a) when such meeting is held, appear at such meeting or otherwise cause the
Stockholder’s Voting Covered Shares to be counted as present thereat for the purpose of establishing a quorum; 

  
 2 

 (b) vote (or execute and return an action by written consent), or cause to be voted at such
meeting (or validly execute and return and cause such consent to be granted with respect to), all of such Stockholder’s Voting Covered Shares owned as of the record date for such meeting (or the date that any written consent is executed by such
Stockholder) in favor of the Transactions and the adoption of the Merger Agreement and any other matters necessary or reasonably requested by the Company or Acquiror for consummation of the Transactions; 

(c) in any other circumstances upon which a consent or other approval is required under the Company’s Governing Documents or the
Investment Agreements or otherwise sought with respect to the Merger Agreement or the Transactions, including the Merger, vote, consent or approve (or cause to be voted, consented or approved) all of such Stockholder’s Voting Covered Shares in
favor thereof; and 
 (d) vote (or execute and return an action by written consent), or cause to be voted at such meeting (or validly
execute and return and cause such consent to be granted with respect to), all of such Stockholder’s Voting Covered Shares against (i) any Acquisition Transaction or any proposal relating to an Acquisition Transaction (in each case, other
than the Transactions); (ii) any merger agreement or merger (other than the Merger Agreement and the Merger), consolidation, combination, sale of substantially all assets, reorganization, recapitalization, dissolution, liquidation or winding up of
or by the Company; and (iii) any proposal, action or agreement that would (A) impede, frustrate, prevent or nullify any provision of this Agreement, the Merger Agreement or the Merger, (B) result in a breach in any respect of any
covenant, representation, warranty or any other obligation or agreement of the Company under the Merger Agreement or (C) result in any of the conditions set forth in Article X of the Merger Agreement not being fulfilled. 

The obligations of each Stockholder specified in this Section 1 shall apply whether or not the Transactions are
recommended by the Board of Directors of the Company or the Board of Directors of the Company has previously recommended the Transactions but changed such recommendation. 

2. No Inconsistent Agreements. Each Stockholder hereby covenants and agrees that such Stockholder shall not (i) enter into any
voting agreement, voting trust or other agreement with respect to any of such Stockholder’s Covered Shares that is inconsistent with such Stockholder’s obligations pursuant to this Agreement, (ii) grant a proxy, power of attorney or
similar right with respect to any of such Stockholder’s Covered Shares that is inconsistent with such Stockholder’s obligations pursuant to this Agreement, or (iii) enter into any other agreement or undertaking that is otherwise
inconsistent with, or would reasonably be expected to interfere with, or would reasonably be expected to prohibit or prevent it from satisfying, its obligations pursuant to this Agreement. 

  
 3 

 3. Termination; Non-Survival of Representations
and Warranties. 
 (a) This Agreement shall terminate upon the earlier to occur of (i) the Closing and (ii) the termination of
the Merger Agreement in accordance with its terms in circumstances where the Closing does not occur (the earlier such date under clause (i) or (ii) being referred to herein as the “Termination Date”), and upon such
termination, this Agreement shall forthwith become void and have no further force or effect, without any liability on the part of any Party; provided, that (A) no such termination shall relieve any Party of any liability for its pre-termination fraud or material breach of this Agreement, (B) this Section 3(a), Section 5(d), Section 5(e), Section 5(f), Section 5(h),
Section 7, and Sections 9 through 21 shall survive any such termination and (C) Section 5(c) shall survive any such termination under clause (i) above until the expiration of the Lock-Up Period (as defined in the Domestication Bylaws). 
 (b) None of the representations or warranties
contained in this Agreement or in any certificate or other writing delivered pursuant hereto shall survive the Closing. 
 4.
Representations and Warranties of the Stockholders. Each Stockholder hereby represents and warrants (severally and not jointly and as to itself only) to Acquiror and the Company as follows: 

(a) Such Stockholder is the sole record owner and beneficial owner (within the meaning of Rule 13d-3
under the Exchange Act) of, and has good, valid and marketable title to, or has a valid proxy to vote, such Stockholder’s Covered Shares, free and clear of any Liens (other than as created by this Agreement or the Governing Documents of the
Company (including, for the purposes hereof, any agreements between or among stockholders of the Company and the Investment Agreements)). As of the date hereof, other than the Covered Shares set forth opposite such Stockholder’s name on
Schedule 1, such Stockholder does not own beneficially or of record any shares of Company Stock (or any securities convertible into shares of Company Stock) or any interest therein. 

(b) Such Stockholder, in each case except as provided in this Agreement or, before giving effect to Section 5(i), the Investment
Agreements or the Governing Documents of the Company, (i) has the right to vote, dispose of and to issue instructions with respect to the matters set forth herein, whether by ownership or by proxy, in each case, with respect to such
Stockholder’s Covered Shares, (ii) has not entered into any voting agreement or voting trust that is inconsistent with such Stockholder’s obligations pursuant to this Agreement, (iii) has not granted a proxy or power of attorney
with respect to any of such Stockholder’s Covered Shares that is inconsistent with such Stockholder’s obligations pursuant to this Agreement, and (iv) has not entered into any agreement or undertaking that is otherwise inconsistent
with, or would interfere with, or prohibit or prevent it from satisfying, its obligations pursuant to this Agreement. 
 (c) Such
Stockholder affirms that (i) if the Stockholder is a natural person, he or she has all the requisite power and authority and has taken all action necessary in order to execute and deliver this Agreement, to perform his or her obligations
hereunder and to consummate the transactions contemplated hereby, and (ii) if the Stockholder is not a natural person, it (A) is a legal entity duly organized, validly existing and, to the extent such concept is applicable, in good
standing under the Laws of the jurisdiction of its organization, and (B) has all 

  
 4 

 
requisite corporate or other power and authority to, and has taken all corporate or other action necessary in order to, execute, deliver and perform its obligations under this Agreement and to
consummate the transactions contemplated hereby. This Agreement has been duly executed and delivered by such Stockholder and, subject to the due execution and delivery of this Agreement by each of the Company and Acquiror, constitutes a legally
valid and binding agreement of such Stockholder enforceable against such Stockholder in accordance with the terms hereof subject to the Enforceability Exceptions. 

(d) Other than the filings, notices and reports pursuant to, in compliance with or required to be made under the Exchange Act, no filings,
notices, reports, consents, registrations, approvals, permits, waivers, expirations of waiting periods or authorizations are required to be obtained by such Stockholder from, or to be given by such Stockholder to, or to be made by such Stockholder
with, any Governmental Authority in connection with the execution, delivery and performance by such Stockholder of this Agreement, the consummation of the transactions contemplated hereby or the Transactions. 

(e) The execution, delivery and performance of this Agreement by such Stockholder does not, and the consummation of the transactions
contemplated hereby and the Transactions will not, constitute or result in (i) a breach or violation of, or a default under, the Governing Documents of such Stockholder (if such Stockholder is not a natural person) or the rights of such
Stockholder’s spouse or domestic partner (if such Stockholder is a natural person and has a spouse or domestic partner, as applicable), (ii) with or without notice, lapse of time or both, a breach or violation of, a termination (or right of
termination) of or a default under, the loss of any benefit under, the creation, modification or acceleration of any obligations under or the creation of a Lien on any of the properties, rights or assets of such Stockholder pursuant to any Contract
binding upon such Stockholder or, assuming (solely with respect to performance of this Agreement and the transactions contemplated hereby), compliance with the matters referred to in Section 4(d), under any applicable Law to which such
Stockholder is subject, (iii) any change in the rights or obligations of any party under any Contract legally binding upon such Stockholder or (iv) any violation of applicable Law, except, in the case of clauses (ii), (iii) or
(iv) directly above, for any such breach, violation, termination, default, creation, acceleration or change that would not, individually or in the aggregate, reasonably be expected to prevent or materially delay or impair such
Stockholder’s ability to perform its obligations hereunder or to consummate the transactions contemplated hereby or the Transactions. 

(f) As of the date of this Agreement, there is no Action pending against such Stockholder or, to the knowledge of such Stockholder, threatened
against such Stockholder that, in any manner, questions the beneficial or record ownership of the Stockholder’s Covered Shares or the validity of this Agreement, or challenges or seeks to prevent, enjoin or materially delay the performance by
such Stockholder of its obligations under this Agreement. 
 (g) Such Stockholder is a sophisticated investor and has adequate information
concerning the business and financial condition of Acquiror and the Company to make an informed decision regarding this Agreement and the Transactions and has independently and based on such information as the Stockholder has deemed appropriate made
its own analysis and decision to enter into this Agreement. Such Stockholder acknowledges that Acquiror and the Company have not made and do not make any representation or warranty, whether express or implied, of any kind or character. Such
Stockholder acknowledges that the agreements contained herein are irrevocable. 

  
 5 

 (h) Such Stockholder understands and acknowledges that Acquiror is entering into the Merger
Agreement in reliance upon such Stockholder’s execution and delivery of this Agreement and the representations, warranties, covenants and other agreements of such Stockholder contained herein. 

(i) No investment banker, broker, finder or other intermediary is entitled to any broker’s, finder’s, financial advisor’s or
other similar fee or commission for which Acquiror or the Company is or could be liable in connection with the Merger Agreement or this Agreement or any of the respective transactions contemplated hereby or thereby, in each case based upon
arrangements made by or on behalf of such Stockholder in his, her or its capacity as a stockholder of the Company. 
 5. Certain
Covenants of the Stockholders. Except in accordance with the terms of this Agreement, each Stockholder hereby covenants and agrees as follows: 

(a) No Transfers Prior to Termination Date. Each Stockholder shall not, prior to the Termination Date (except, in each case, pursuant to
the Merger Agreement), (i) directly or indirectly sell, transfer, hypothecate, pledge, encumber, assign, hedge, swap, convert or otherwise dispose of (including by merger (including by conversion into securities or other consideration), by tendering
into any tender or exchange offer, by testamentary disposition, by operation of Law or otherwise), either voluntarily or involuntarily, any of its Covered Shares, (ii) enter into any Contract or option with respect to any transaction specified
in clause (i) or any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any of its Covered Shares, whether any such transaction is to be settled by delivery of such
securities, in cash or otherwise, or (iii) publicly announce any intention to effect any transaction specified in clauses (i) or (ii) (any transaction specified in clauses (i), (ii) or (iii), a “Transfer”);
provided, however, that the foregoing shall not restrict Transfers (I) to (w) such Stockholder’s officers or directors, (x) any affiliates or family members of such Stockholder’s officers or directors, (y) any
members or partners of such Stockholder or their affiliates, any affiliates of such Stockholder, or any employees of such affiliates; (z) to another Stockholder of the Company that is a party to this Agreement and bound by the terms and
obligations hereof, (II) in the case of an individual, by gift to a member of such individual’s immediate family or to a trust, the beneficiary of which is a member of such individual’s immediate family, an affiliate of such
individual or to a charitable organization; (III) in the case of an individual, by virtue of laws of descent and distribution upon death of such individual; or (IV) in the case of an individual, pursuant to a qualified domestic relations
order (a “Permitted Transfer”); provided, further, that any Permitted Transfer shall be permitted only if, as a precondition to such Transfer, the transferee agrees in a writing, reasonably satisfactory in form
and substance to Acquiror, to assume all of the obligations of the transferring Stockholder under, and be bound by all of the terms of, this Agreement; provided, further, that any Transfer permitted under this Section 5(b) shall not
relieve the transferring Stockholder of its obligations under this Agreement. Any Transfer in violation of this Section 5(b) shall be null and void. 

  
 6 

 (b) Post-Closing Lock-Up. Each Stockholder
hereby acknowledges that it has read the Domestication Bylaws, including Section 42 thereof, and understands that such section provides that certain of such Stockholder’s Covered Shares will be subject to Transfer restrictions (i.e., a “lock-up”) following the Closing, as and to the extent set forth therein. Accordingly, each Stockholder hereby agrees to be bound by and comply with Section 42 of the Domestication Bylaws as if such
section was set forth herein and made a part hereof. Notwithstanding anything to the contrary herein, to the extent the Board of Directors of Acquiror waives or repeals, or otherwise relaxes, any of the
lock-up restrictions set forth in Section 42 of the Domestication Bylaws (whether acting pursuant to Section 42 of the Domestication Bylaws or otherwise), such lock-up
restrictions shall be identically waived, repealed or relaxed, as applicable, with respect to the Stockholders. 
 (c) No Actions to
Breach Agreement. Each Stockholder shall not take any action that would make any representation or warranty of such Stockholder contained herein untrue or incorrect or have the effect of preventing or disabling such Stockholder from performing
its obligations under this Agreement. 
 (d) Maintenance of Records. Each Stockholder hereby authorizes Acquiror and the Company to
maintain a copy of this Agreement at either its executive office or registered office. 
 (e) Binding Effect of Merger Agreement.
Each Stockholder hereby acknowledges that it has read the Merger Agreement and this Agreement and has had the opportunity to consult with its tax, legal and other advisors with respect thereto and hereto. Each Stockholder shall be bound by and
comply with Section 9.04(a) (Exclusivity) and Section 9.06 (Confidentiality; Publicity) of the Merger Agreement (and any relevant definitions contained in any such sections) as if such Stockholder was an original signatory to
the Merger Agreement with respect to such provisions and each reference to the Company in such provision referred to such Stockholder. 

(f) Closing Date Deliverables. On the Closing Date, each Stockholder that is requested by the Company to execute the Registration
Rights Agreement shall deliver to Acquiror and the Company a duly executed copy of the Registration Rights Agreement, in substantially the form attached as Exhibit C to the Merger Agreement. 

(g) No Challenges; Waiver of Appraisal Rights. Each Stockholder shall not commence, join in, facilitate, assist or encourage, and shall
take all actions necessary to opt out of any class in any class action with respect to, any claim, derivative or otherwise, against any of the Acquiror Parties, the Company, the Sponsor, any of their respective Affiliates or any of the respective
Representatives (including directors, officers and employees) of the foregoing Persons, or any of the respective successors or assigns of any of the foregoing Persons, challenging the validity of, or seeking to enjoin the operation of, any provision
of this Agreement or alleging a breach of any fiduciary duty of any Person in connection with the evaluation, negotiation or entry into the Merger Agreement or any other Transaction Agreement or the consummation of the Transactions. Each Stockholder
hereby irrevocably and unconditionally waives, and agrees not to assert, exercise or perfect (or attempt to exercise, assert or perfect), any rights of appraisal or rights to dissent from the Merger or appraisal or dissenters’ rights that it
may at any time have under applicable Laws, including Section 262 of the DGCL. 

  
 7 

 (h) Termination of Affiliate Agreements and Certain Other Agreements. Each
Stockholder, by this Agreement with respect to its Covered Shares, severally and not jointly, hereby agrees to take all action necessary to terminate, subject to and effective immediately prior to the Closing, (a) all Affiliate Agreements to
which such Stockholder is party (including the Investment Agreements) other than those that are set forth on Section 7.07 of the Company Disclosure Letter (a redacted version of which, showing only the surviving Affiliate Agreements applicable
to such Stockholder, has previously been reviewed by such Stockholder); (b) all Investment Agreements to which such Stockholder or its Affiliates is a party; and (c) any rights under any letter or agreement providing for redemption rights, put
rights, purchase rights or other similar rights not generally available to stockholders of the Company. The Company and each Stockholder hereby waives any right to notice, right to consent to transfer, right of first offer, right of first refusal or
similar rights with respect to the disposition of any shares of Company Stock in the Transaction, in each case that such Stockholder may have under any Investment Agreements or under the Company’s Organizational Documents. 

(i) Acknowledgment of Treatment of Company Warrants. Each Stockholder, to the extent such Stockholder is a holder of Company Warrants,
acknowledges and agrees to the treatment of Company Warrants as described in Section 3.05 of the Merger Agreement. 
 (j) Release of
Claims. Effective as of, and conditioned upon occurrence of, the Closing, each Stockholder, for itself and on behalf of each of its Affiliates and each of their respective successors (each, a “Releasing Party”), hereby unequivocally,
voluntarily, knowingly, willingly, unconditionally, completely and, irrevocably releases, acquits, exculpates and forever waives and relinquishes all claims, suits, debts, demands, liabilities, setoffs, counterclaims, actions, manners of action and
causes of action of whatever kind or nature, whether known or unknown (collectively, “Claims”), which any Releasing Party has, may have or might have or may assert now or in the future, against the Company and its Subsidiaries and their
respective Representatives (in each case, solely in their capacity as such), successors and permitted assigns, and, after the Closing, the Acquiror and its Subsidiaries, and each of their respective officers, directors, owners, partners, managers or
employees (in each case, solely in their capacity as such) (collectively, the “Released Parties”) to the extent arising out of, based upon or resulting from any Contract, transaction, event, circumstance, action, failure to act or
occurrence of any sort or type, whether known or unknown, and which, in each and every case, occurred, existed, was taken, permitted, incurred or begun at or prior to the Closing, in each case solely with regard to the Company, the business or
operations of the Company prior to the Closing or the Transactions; provided, that nothing contained in this Section 5(j) shall be construed as a waiver of any rights under (i) this Agreement, (ii) any other Transaction
Agreement to which any Releasing Party is party, (iii) if such Stockholder is an employee of the Company, rights to accrued but unpaid salary, bonuses, expense reimbursements (in accordance with Company’s employee expense reimbursement
policy), accrued vacation and other benefits under the Company’s employee benefit plans, or (iv) any indemnification, employment or other similar arrangements (including any such arrangement providing for exculpation or advancement of
expenses), including any rights to indemnification, exculpation, advancement of expense or similar rights set forth in the Governing Documents of the Company, any indemnification agreement between the Company and such Stockholder, or as provided by
law or any directors’ and officers’ liability insurance. 

  
 8 

 (k) Update of Schedule 1. If any Stockholder acquires record or beneficial ownership
of any Covered Shares following the date hereof (or becomes aware, following the date hereof, of its record or beneficial ownership of any Covered Shares as of the date hereof, which shares are not already set forth on Schedule 1), such
Stockholder shall promptly notify the Company and Acquiror in writing (email being sufficient), and Schedule 1 shall be updated to reflect such Stockholder’s ownership of such additional Covered Shares. 

6. Further Assurances. From time to time, at Acquiror’s request and without further consideration, each Stockholder shall execute
and deliver such additional documents and take all such further action as may be necessary or reasonably requested to effect the actions and consummate the Transactions and the transactions contemplated hereby. 

7. Disclosure. Such Stockholder hereby authorizes the Company and Acquiror to publish and disclose in any announcement or disclosure
relating to the Transactions, including any such announcement or disclosure required or requested by the SEC (or as otherwise required or requested pursuant to any applicable Laws or any other Governmental Authorities), such Stockholder’s
identity and ownership of the Covered Shares and the nature of such Stockholder’s obligations under this Agreement and, a copy of this Agreement, if deemed appropriate by Acquiror and the Company. Each Stockholder will promptly provide any
information reasonably requested in writing by Acquiror or the Company for any regulatory application or filing made or approval sought in connection with the transactions contemplated by the Merger Agreement (including filings with the SEC). 

8. Changes in Company Stock. In the event (i) of a stock split, stock dividend or distribution, or any change in Company Stock by
reason of any split-up, reverse stock split, recapitalization, combination, reclassification, exchange of shares or the like, (ii) the Stockholder purchases or otherwise acquires beneficial ownership of
any Company Stock or (iii) the Stockholder acquires the right to vote or share in the voting of any Company Stock, the term “Covered Shares” shall be deemed to refer to and include such shares as well as all such stock
dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction. 

9. Amendment and Modification. This Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct
or otherwise, except by an instrument in writing signed by Acquiror, the Company and each Stockholder charged with such amendment, modification or supplement. 

10. Waiver. No failure or delay by any Party exercising any right, power or privilege hereunder shall operate as a waiver thereof nor
shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies of the Parties hereunder are cumulative and are not exclusive of any rights
or remedies which they would otherwise have hereunder. Any agreement on the part of a Party to any such waiver shall be valid only if set forth in a written instrument executed and delivered by such Party. 

  
 9 

 11. Notices. All notices and other communications hereunder shall be in writing and shall be
deemed given if delivered personally, by email (with confirmation of receipt) or sent by a nationally recognized overnight courier service, such as Federal Express, to the Parties at the following addresses (or at such other address for a Party as
shall be specified by like notice made pursuant to this Section 11): 
 if to the Stockholder, to the address or email address set
forth opposite such Stockholder’s name on Schedule 1, or in the absence of such address or email address being set forth on Schedule 1, the address (including email) set forth in the Company’s books and records, 

with a copy (which shall not constitute notice) to: 

Cooley LLP 
 55 Hudson Yards

 New York, NY 10001-2157 

Attention:    Adam Dinow, David Silverman, Rupa Briggs 

Email:          adinow@cooley.com; david.silverman@cooley.com; 

rbriggs@cooley.com 
 if to the
Company, to it at: 
 Rigetti Holdings, Inc. 

775 Heinz Avenue 
 Berkeley, CA
94710 
 Attention:    Chad Rigetti; Taryn Naidu; Rick Danis 

Email:          chad@rigetti.com; taryn@rigetti.com; rick@rigetti.com 

with a copy (which shall not constitute notice) to: 

Cooley LLP 
 55 Hudson Yards

 New York, NY 10001-2157 

Attention:    Adam Dinow; David Silverman; Rupa Briggs 

Email:          adinow@cooley.com; david.silverman@cooley.com;
rbriggs@cooley.com 

  
 10 

 if to Acquiror prior to the Closing, to it at: 

Supernova Partners Acquisition Company II, Ltd. 

4301 50th Street, NW 
 Suite
300, PMB 1044 
 Washington, DC 20016 

Attention:     Robert Reid, CEO; Michael Clifton, CFO 

Email:          robert@supernovaspac.com; michael@supernovaspac.com 

with a copy (which shall not constitute notice) to: 

Latham & Watkins LLP 

555 Eleventh Street, 
 NW Suite
1000 
 Washington, DC 20004-1304 

Attention:     Nicholas P. Luongo; Ryan J. Maierson; Patrick H. Shannon 

Email:          nick.luongo@lw.com; ryan.maierson@lw.com; 

patrick.shannon@lw.com 
 if to
Acquiror after the Closing, to it at: 
 Rigetti Computing Inc. 

775 Heinz Avenue 
 Berkeley, CA
94710 
 Attention:    Chad Rigetti; Taryn Naidu; Rick Danis 

Email: chad@rigetti.com; taryn@rigetti.com; rick@rigetti.com 

In addition to the foregoing, in the case of any pre-Closing notices sent by any Stockholder to any
other Stockholder or the Company, or sent by the Company to any Stockholder, copies shall also be sent to Acquiror (to the person specified to receive pre-Closing notices on behalf of Acquiror) and to
Latham & Watkins LLP (to the persons referenced above). 
 12. No Ownership Interest. Nothing contained in this Agreement
shall be deemed to vest in Acquiror any direct or indirect ownership or incidence of ownership of or with respect to the Covered Shares of any Stockholder. All rights, ownership and economic benefits of and relating to the Covered Shares of each
Stockholder shall remain vested in and belong to such Stockholder, and Acquiror shall have no authority to direct any Stockholder in the voting or disposition of any of such Stockholder’s Covered Shares, except as otherwise provided herein.

 13. Entire Agreement; Time of Effectiveness. This Agreement and the Merger Agreement constitute the entire agreement and
understanding, and supersede all prior agreements and understandings, both written and oral, between the Parties with respect to the subject matter hereof. 

14. No Third-Party Beneficiaries. Each Stockholder hereby agrees that its representations, warranties and covenants set forth herein
are solely for the benefit of Acquiror and the Company in accordance with and subject to the terms of this Agreement, and this Agreement is not intended to, and does not, confer upon any Person other than the Parties, any

  
 11 

 
rights or remedies hereunder, including the right to rely upon the representations, warranties and covenants set forth herein, and the Parties hereby further agree that this Agreement may only be
enforced against, and any Action that may be based upon, arise out of or relate to this Agreement, or the negotiation, execution or performance of this Agreement, may only be made against, the Persons expressly named as parties to this Agreement.

 15. Governing Law and Venue; Service of Process; Waiver of Jury Trial. 

(a) This Agreement, and all claims or causes of action based upon, arising out of, or related to this Agreement or the transactions
contemplated hereby, shall be governed by, and construed in accordance with, the internal Laws of the State of Delaware, including its statute of limitations, without giving effect to principles or rules of conflict of laws to the extent such
principles or rules would require or permit the application of the Laws or statute of limitations of another jurisdiction. 
 (b) Any Action
based upon, arising out of or related to this Agreement or the transactions contemplated hereby may only be brought in the Court of Chancery of the State of Delaware or, if such court lacks jurisdiction, the state and federal courts in the State of
Delaware, and each of the Parties irrevocably submits to the exclusive jurisdiction of each such court in any such Action, waives any objection it may now or hereafter have to personal jurisdiction, venue or to convenience of forum, agrees that all
claims in respect of the Action shall be heard and determined only in any such court, and agrees not to bring any Action arising out of or relating to this Agreement or the transactions contemplated hereby in any other court. Nothing herein
contained shall be deemed to affect the right of any Party to serve process in any manner permitted by Law or to commence legal proceedings or otherwise proceed against any other Party in any other jurisdiction, in each case, to enforce judgments
obtained in any Action brought pursuant to this Section 15(b). 
 (c) EACH OF THE PARTIES HEREBY KNOWINGLY, INTENTIONALLY,
VOLUNTARILY AND IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY ACTION BASED UPON, ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 

16. Assignment; Successors. Neither this Agreement nor any of the rights, interests or obligations hereunder shall (a) be assigned
by any of the Stockholders, in whole or in part (whether by operation of Law or otherwise), without the prior written consent of Acquiror and the Company or (b) be assigned by Acquiror or the Company, in whole or in part (whether by operation
of law or otherwise), without the prior written consent of the Company (in the case of an attempted assignment by Acquiror) or Acquiror (in the case of an attempted assignment by the Company). Any such assignment without such consent shall be null
and void. This Agreement shall be binding upon, inure to the benefit of and be enforceable by the Parties and their respective successors and permitted assigns. 

  
 12 

 17. Enforcement. The Parties agree that irreparable damage (for which monetary
damages, even if available, would not be an adequate remedy) would occur, and that the Parties would not have any adequate remedy at law, in the event that any of the provisions of this Agreement were not performed in accordance with their specific
terms or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to specific performance, an injunction or injunctions, or other equitable relief to prevent breaches or threatened breaches of this Agreement and to
enforce specifically the terms and provisions of this Agreement, including each Stockholder’s obligations under Section 1, without proof of actual damages or otherwise (and each Party hereby waives any requirement for the securing or
posting of any bond in connection with such remedy), this being in addition to any other remedy to which they are entitled at Law or in equity. Each Party acknowledges and agrees that the right of specific enforcement is an integral part of the
transactions contemplated hereby and that, without such right, none of the Parties would have entered into this Agreement. Each Party agrees that it will not oppose the granting of specific performance and other equitable relief on the basis that
the other Parties have an adequate remedy at Law. 
 18. Severability. If any term or other provision of this Agreement is held by a
court of competent jurisdiction or other authority to be invalid, void, unenforceable or against its regulatory policy, the remainder of the terms and provisions of this Agreement shall remain in full force and effect and shall in no way be
affected, impaired or invalidated. Upon such a determination, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the
transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible. 
 19. Counterparts. This
Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement, it being understood that each Party need not sign the same counterpart. Signatures delivered electronically or by facsimile shall be
deemed to be original signatures. 
 20. Interpretation and Construction. The words “hereof,” “herein” and
“hereunder” and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The descriptive headings used herein are inserted for convenience of reference only
and are not intended to be part of or to affect the meaning or interpretation of this Agreement. References to Sections and Schedules are to Sections and Schedules of this Agreement, respectively, unless otherwise specified. Any singular term in
this Agreement shall be deemed to include the plural, and any plural term the singular. The definitions contained in this Agreement are applicable to the masculine as well as to the feminine and neuter genders of such term. Whenever the words
“include,” “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation,” whether or not they are in fact followed by those words or words of like
import. “Writing,” “written” and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any statute shall be deemed to refer to
such statute as amended from time to time and to any rules or regulations promulgated thereunder. References to any person include the successors and permitted assigns of that person. References from or through any date mean, unless otherwise
specified, from and including such date or through and including such date, respectively. In the event an ambiguity or question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the Parties, and no
presumption or burden of proof will arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement. The term “or” is not exclusive. 

  
 13 

 21. Capacity as a Stockholder or Proxy Holder. Notwithstanding anything herein to the
contrary, each Stockholder is signing this Agreement solely in such Stockholder’s capacity as a stockholder or proxy holder of the Company, and not in any other capacity, and this Agreement shall not limit, prevent or otherwise affect the
actions of such Stockholder or any Affiliate or Representative thereof, or any of their respective Affiliates, in his or her capacity, if applicable, as an officer or director of the Company (or any Subsidiary of the Company) or any other Person,
including in the exercise of his or her fiduciary duties as a director or officer of the Company or any Subsidiary of the Company. No Stockholder shall be liable or responsible for any breach, default, or violation of any representation, warranty,
covenant or agreement hereunder by any other Stockholder that is also a Party and each Stockholder shall solely be required to perform its obligations hereunder in its individual capacity. 

[The remainder of this page is intentionally left blank.] 

  
 14 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed (where applicable,
by their respective officers or other authorized Persons thereunto duly authorized) as of the date first written above. 
  

			
	SUPERNOVA PARTNERS ACQUISITION COMPANY II, LTD.
		
	By:	 	 
	Name:	 	
	Title:	 	

  

			
	RIGETTI HOLDINGS, INC.
		
	By:	 	 
	Name:	 	
	Title:	 	

  
 [Signature Page to
Company Holders Support Agreement] 

 
			
	[STOCKHOLDER]
		
	By:	 	 
	Name:	 	[•]
	Title:	 	[•]

  
 [Signature Page to
Company Holders Support Agreement] 

 Schedule 1 

Covered Shares 
  

																	
	 Stockholder Name
	  	Number of Shares of
Company Class A
Common Stock	 	 	Number of Shares of
Company Class B
Common Stock	 	 	Number of Shares of
Company Series C
Preferred Stock	 	 	Number of Shares of
Company Series C-1
Preferred Stock	 
	 [_____]
	  	 	[_____	] 	 	 	[_____	] 	 	 	[_____	] 	 	 	[_____	] 
	 [_____]
	  	 	[_____	] 	 	 	[_____	] 	 	 	[_____	] 	 	 	[_____	] 
	 [_____]
	  	 	[_____	] 	 	 	[_____	] 	 	 	[_____	] 	 	 	[_____	] 

  
 Schedule 1-1Exhibit 10.1

      

      

      Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark
      “[***]”

    

    

     

    

    

    

    EXECUTIVE EMPLOYMENT AGREEMENT

     

    This Executive Employment Agreement (the “Agreement”) is entered into as of October 4, 2021, and effective as of October 18, 2021 (the “Effective
      Date”) by and between PDS Biotechnology Corporation, a Delaware corporation (the “Company”), and Matthew Hill (“Executive”).

     

    W I T N E S S E T H :

     

    WHEREAS, the Company wishes to employ Executive in the role of Chief Financial Officer;

     

    WHEREAS, Executive and the Company desire (i) to enter into this Agreement to govern the employment of the Executive, and (ii) for this Agreement to
      supersede and replace any and all agreements, terms, and discussions between the parties; and

     

    WHEREAS, the Executive desires to accept employment with the Company pursuant to the terms and conditions of this Agreement.

     

    NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein and for other good and valuable consideration, the receipt and
      sufficiency of which are mutually acknowledged, the Company and Executive hereby agree as follows:

     

    Section 1.          Definitions.

     

    (a)          “Accrued Obligations” shall mean (i) all accrued but unpaid Base Salary through the Date of Termination, (ii) any unpaid or unreimbursed business expenses incurred in accordance with Section 6 hereof, and (iii) all vested
          benefits (including, if applicable, equity awards) in accordance with the terms of the governing documents.

     

    (b)          “Base Salary” shall mean the salary provided for in Section 4(a) hereof, as adjusted from time to time.

     

    (c)          “Board” shall mean the Board of Directors of the Company.

     

    (d)          “Cause” shall mean (i) Executive’s failure, neglect, or refusal to perform in any material respect to Executive’s duties and responsibilities under this
            Agreement  (in each case, except where due to a Disability, sickness or illness); (ii) any act of Executive that has, or could reasonably be expected to have, the effect of injuring the business of the Company or its subsidiaries in any material respect; (iii) Executive’s conviction of, or plea of guilty or no contest to: (x) a felony or (y) any other criminal charge that has, or could be reasonably expected
            to have, an adverse impact on the performance of Executive’s duties to the Company or otherwise result in material injury to the reputation or business of the Company or any of its subsidiaries; (iv) Executive’s commission of an act of fraud or
            embezzlement against the Company or any of its subsidiaries; (v) any material violation by Executive of the policies of the Company, including but not limited to those relating to sexual harassment or business conduct, and those otherwise set
            forth in the manuals or statements of policy of the Company, as may be amended from time to time; (vi) Executive’s material violation of federal or state securities laws; or (vii) Executive’s material breach of this Agreement or material breach
            of the Confidentiality and Invention Assignment Agreement.

     

    
      1

      
        

    

    (e)          “Code” shall mean the Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder.

     

    (f)          “Confidentiality and Invention Assignment Agreement” shall mean the Employee Confidentiality and Invention Assignment Agreement, executed by the Company and Executive O and attached hereto as Exhibit A.

     

    (g)          “Date of Termination” shall mean the date on which Executive’s employment terminates.

     

    (h)        “Disability” shall mean any physical or mental disability or infirmity of Executive that prevents Executive from performing Executive’s duties with or without a reasonable accommodation for a period of (i) ninety (90)
          consecutive days or (ii) one hundred twenty (120) non-consecutive days during any twelve (12) month period.  Any question as to the existence, extent, or potentiality of Executive’s Disability upon which Executive and the Company cannot agree
          shall be determined by a qualified, independent physician selected by the Company and approved by Executive (which approval shall not be unreasonably withheld).  The determination of any such physician shall be final and conclusive for all
          purposes of this Agreement.  Executive understands that Executive is a “key employee” in connection with any leave qualifying for coverage under the Family and Medical Leave Act (“FMLA”).

     

    (i)          “Good Reason” shall mean, without Executive’s written consent, (i) a material diminution in Executive’s title, duties, or responsibilities as set forth in Section 3 hereof; (ii) a material reduction in Base Salary as set
          forth in Section 4(a) hereof (other than pursuant to a reduction applicable to all similarly situated executives); (iii) any material breach of this Agreement by the Company (other than a provision that is covered by clause (i) or (ii)). 
          Notwithstanding the foregoing, in the event that the Company reasonably believes that Executive may have engaged in conduct that could constitute Cause hereunder, the Company may, in its sole and absolute discretion, suspend Executive’s duties or
          employment, and in no event shall any such suspension constitute an event pursuant to which Executive may terminate employment with Good Reason or otherwise constitute a breach of this Agreement by the Company; provided, that no such suspension shall alter the Company’s obligations under this Agreement during such period of suspension.

     

    (j)          “Release of Claims” shall mean a separation agreement in a form acceptable to the Company under which Executive releases the Company and certain other persons and entities from any and all claims and causes of action and
          the execution of which is a condition precedent to Executive’s eligibility for the payments and benefits described in Sections 7(d) and 7(e).

     

    (k)          “Severance Benefits” shall mean continued payment of Base Salary during the Severance Term, in accordance with the Company’s regular payroll practices.

     

    (l)          “Severance Term” shall mean a period commencing on the first pay day following the effective date of the Release of Claims executed by Executive in connection with a termination of Executive’s employment without Cause or
          resignation with Good Reason and continuing for a period of twelve (12) months.

     

    Section 2.          Acceptance and Term.

     

    The Company agrees to employ Executive on an at-will basis, and Executive agrees to accept such employment and serve the Company, in accordance with
      the terms and conditions set forth herein.  The term of employment under this Agreement (referred to herein as the “Term”) shall commence on the Effective Date and shall continue until terminated by either party at any time, subject to the provisions
      herein.

     

    
      2

      
        

    

    Section 3.          Position, Duties, and Responsibilities; Place of Performance.

     

    (a)          Position, Duties and Responsibilities.  During the Term, Executive shall be engaged to serve as the Chief Financial Officer of the Company (together with such other position or positions consistent with Executive’s title
          or as the Company shall specify from time to time) and shall have such duties and responsibilities as are commensurate therewith and such other duties as may be assigned and/or prescribed from time to time by Executive’s supervisor and/or the
          Board.  Executive shall report to the President and Chief Executive Officer of the Company.

     

    (b)          Performance. Executive shall devote Executive’s full business time, attention, skill, and best efforts to the performance of Executive’s duties under this Agreement and shall not engage in any other business or occupation
          during the Term, including, without limitation, any activity that (x) conflicts with the interests of the Company, (y) interferes with the proper and efficient performance of Executive’s duties for the Company, or (z) interferes with Executive’s
          exercise of judgment in the Company’s best interests.  Notwithstanding the foregoing, nothing herein shall preclude Executive from (i) serving, with the prior written consent of the Board, as a member of the boards of directors or advisory boards
          (or their equivalents in the case of a non-corporate entity) of non-competing businesses, non-profits and charitable organizations, (ii) engaging in charitable activities and community affairs, and (iii) managing Executive’s personal investments
          and affairs; provided, however, that the activities set out in clauses (i), (ii), and (iii) shall be limited by Executive so as not to interfere, individually or in the
          aggregate, with the performance of Executive’s duties and responsibilities hereunder and so that no such position creates an actual or potential conflict of interest.  Executive represents that, attached hereto as Exhibit B, is a comprehensive list of all outside professional activities with which Executive is currently involved or reasonably expects to become involved.  Company hereby acknowledges that Executive’s
          participation in the foregoing activities at the participation levels as of the Effective Date is permitted under this paragraph, provided that the same do not interfere, individually or in the aggregate, with the performance of Executive’s
          duties and responsibilities hereunder or create an actual or potential conflict of interest.  In the event that, during Executive’s employment by the Company, Executive desires to engage in other non-competitive outside professional activities,
          not included on such list, Executive will first seek written approval from the President and Chief Executive Officer and such approval shall not be unreasonably withheld.

     

    Section 4.          Compensation.

     

    (a)          Base Salary. During the Term, in exchange for Executive’s satisfactory performance of Executive’s duties and responsibilities, Executive will be paid a Base Salary at the rate of $350,000 per annum, payable in accordance with the Company’s regular salary payment schedule and subject to applicable taxes and withholdings.  The Base Salary of the Executive for
          subsequent years of this Agreement may be increased, decreased, or may stay the same, depending on the Executive’s performance and the performance of the Company.

     

    (b)         Annual Bonus. In addition to Executive’s Base Salary, during the Term, Executive will be eligible to earn an annual discretionary performance-based bonus, with a target bonus opportunity equal to 35% of the Base Salary.  Performance metrics with respect to said bonus will be determined by the Board or the compensation committee of the Board.  The first
          Annual Bonus after execution of this Agreement for performance in year 2021 shall be at the discretion of the Board, provided that Executive will receive a percentage of the Bonus comparable to other executives for that portion of bonus assigned
          to Company performance in 2021.  For specificity, the Executive, as it pertains to the first Annual Bonus for performance in year 2021, is eligible for the full bonus opportunity of 35% of the Base Salary provided at the discretion of the Board
          and there is no proration of the first Annual Bonus based on time worked for the Company. Executive shall be eligible for said bonus only if Executive is employed on the last day of the performance period.  Any earned annual bonus will be paid by
          March 15th of the year following the year in which the applicable performance period ends and Executive will need to be employed by the Company at the time the annual bonus is paid.

     

    
      3

      
        

    

    (c)         Equity Awards. In addition to Executive’s Base Salary and bonus eligibility, as a material inducement to Executive joining the Company, Executive will receive a nonqualified stock option to purchase 202,800 shares of the Company’s common stock under the PDS Biotechnology Corporation
          2019 Inducement Plan (as amended, the “Inducement Plan”), subject to the approval of the Board and the requirements under the inducement grant exception under Nasdaq Rule 5635(c)(4). The exercise price of the options will be at fair market value
          on the date of grant and shall be subject to 4 year vesting period with 25% of the options vesting on the first anniversary of the grant date and the remaining options vesting in equal parts over the 36 month period thereafter.  The terms of this
          grant shall be subject to and governed by the Inducement Plan and a stock option agreement between Executive and the Company.  During the Term, Executive shall be eligible to be granted such additional equity awards by the Company, as determined
          by the Board or the compensation committee of the Board, in its sole discretion.

     

    Section 5.          Executive Benefits.

     

    During the Term, Executive shall be offered participation in health insurance and other benefits provided generally to similarly situated executives
      of the Company, subject to the terms, conditions and eligibility requirements of the applicable benefit plans (which shall govern).  Executive shall be eligible for the same number of holidays and vacation days as well as any other benefits, except
      those excluded herein, in each case, as are generally allowed to similarly-situated executives of the Company in accordance with the Company policy as in effect from time to time.  Nothing contained herein shall be construed to limit the Company’s
      ability to amend, suspend, or terminate any benefit plan or policy at any time without providing Executive notice, and the right to do so is expressly reserved.

     

    Section 6.          Reimbursement of Business Expenses.

     

    During the Term, the Company shall reimburse Executive for documented, out-of-pocket business expenses reasonably incurred by Executive in the course
      of performing Executive’s duties and responsibilities hereunder, which are consistent with the Company’s policies in effect from time to time with respect to business expenses, and subject to the Company’s requirements with respect to reporting of
      such expenses.

     

    Section 7.          Termination of Employment.

     

    (a)          General. Executive’s employment with the Company, and the Term, shall terminate upon the earliest to occur of: (i) Executive’s death, (ii) a termination by reason of a Disability, (iii) a termination by the Company with
          or without Cause, or (iv) a termination by Executive with or without Good Reason.  Notwithstanding anything herein to the contrary, the payment (or commencement of a series of payments) hereunder of any nonqualified deferred compensation (within
          the meaning of Section 409A of the Code) upon a termination of employment shall be delayed until such time as Executive has also undergone a “separation from service” as defined in Treas. Reg. 1.409A-1(h), at which time such nonqualified deferred
          compensation (calculated as of the date of Executive’s termination of employment hereunder) shall be paid (or commence to be paid) to Executive on the schedule set forth in this provision as if Executive had undergone such termination of
          employment (under the same circumstances) on the date of Executive’s ultimate “separation from service.”

     

    
      4

      
        

    

    (b)         Termination Due to Death or Disability. Executive’s employment under this Agreement shall terminate automatically upon Executive’s death.  Executive’s employment may be terminated by the Company, in its sole discretion,
          upon the occurrence of a Disability, with such termination to be effective upon Executive’s receipt of written notice of such termination.  In the event of Executive’s termination as a result of Executive’s death or Disability, Executive or
          Executive’s estate or beneficiaries, as the case may be, shall be entitled only to the Accrued Obligations, and Executive shall have no further rights to or interest in any compensation or any other benefits under this Agreement.

     

    (c)          Termination by the Company with Cause.

     

    	

          	(i)	
            The Company may terminate Executive’s employment at any time with Cause, effective upon Executive’s receipt of written notice of such termination; provided, however, that with respect to any Cause
              termination relying on clause (i), (ii), (v) or (vii) of the definition of Cause set forth in Section 1(d) hereof, to the extent that such act or acts or failure or failures to act are curable, Executive shall be given ten (10) days’ written
              notice by the Company of its intention to terminate him with Cause, such notice to state the act or acts or failure or failures to act that constitute the grounds on which the proposed termination with Cause is based, and such termination
              shall be effective at the expiration of such ten (10) day notice period unless Executive has fully cured such act or acts or failure or failures to act, to the Company’s complete satisfaction.

          

     

    	

          	(ii)	
            In the event that the Company terminates Executive’s employment with Cause, Executive shall be entitled only to the Accrued Obligations.  Following such termination of Executive’s employment with
              Cause, except as set forth in this Section 7(c)(ii), Executive shall have no further rights to or interest in any compensation or any other benefits under this Agreement or otherwise.  For the avoidance of doubt, Executive’s sole and
              exclusive remedy upon a termination of employment by the Company with Cause shall be receipt of the Accrued Obligations.

          

     

    (d)        Termination by the Company without Cause. The Company may terminate Executive’s employment at any time without Cause, immediately upon written notice thereof or on such later date as may be set forth in the notice of
          termination.  In the event that, during the Term, Executive’s employment is terminated by the Company without Cause (other than due to death or Disability), Executive shall be eligible for the Accrued Obligations, and, provided that Executive
          fully executes (and does not revoke) the Release of Claims as described in Section 7(h), Executive shall also be eligible for (i) the Severance Benefits and (ii) reimbursement for Executive’s (and Executive’s eligible dependents’) health care
          continuation (COBRA) premiums for twelve (12) months following such termination (provided that (A) such COBRA benefits shall not be provided beyond the date on which Executive obtains comparable coverage from a subsequent employer and (B) such
          benefits shall not be provided to the extent that the Company determines that it would result in any fine, penalty or violation of law for being a discriminatory benefit or otherwise) (the “COBRA
              Benefits”).  Notwithstanding the foregoing, the Severance Benefits and the COBRA Benefits shall immediately terminate, and the Company shall have no further obligations to Executive with respect thereto, and any Severance Benefits
          and COBRA Benefits that were provided will be reimbursed or repaid promptly by Executive to the Company (except that Executive may retain the first $1,000 of Severance Benefits, which Executive acknowledges and agrees will be adequate
          consideration for the Release of Claims), in the event that Executive breaches any provision of the Confidentiality and Invention Assignment Agreement or the Release of Claims.  Any such termination, reimbursement or repayment of Severance
          Benefits or COBRA Benefits shall have no effect on the Release of Claims or any of Executive’s post-employment obligations to the Company.  Following termination of Executive’s employment by the Company without Cause, except as set forth in this
          Section 7(d), Executive shall have no further rights to any compensation or any other benefits under this Agreement. For the avoidance of doubt, Executive’s sole and exclusive remedy upon a termination of employment by the Company without Cause
          shall be receipt of the Severance Benefits and the COBRA Benefits, subject to Executive’s execution and non-revocation of the Release of Claims, and the Accrued Obligations.

     

    
      5

      
        

    

    (e)        Termination by Executive with Good Reason. Executive may terminate Executive’s employment with Good Reason by providing the Company ninety (90) days’ written notice setting forth in reasonable specificity the event that
          constitutes Good Reason, which written notice, to be effective, must be provided to the Company within thirty (30) days after the occurrence of such event.  During such ninety (90) day notice period, the Company shall have a cure right.  If the
          Company does not cure such event constituting Good Reason within such 90-day period, Executive shall have thirty (30) days from the end of such cure period to terminate Executive’s employment with Good Reason by providing written notice thereof
          to the Company (and if Executive fails to provide such notice within such 30-day period, Executive will be deemed to have accepted the Company’s cure of the event constituting Good Reason or otherwise waived such Good Reason event).  In the event
          of such a Good Reason termination during the Term, Executive shall be entitled to the same payments and benefits as provided in Section 7(d) hereof for a termination by the Company without Cause, subject to the same conditions on payment and
          benefits (and forfeiture and repayment) as described in Section 7(d) hereof.  Following such termination of Executive’s employment by Executive with Good Reason, except as set forth in this Section 7(e), Executive shall have no further rights to
          any compensation or any other benefits under this Agreement.  For the avoidance of doubt, Executive’s sole and exclusive remedy upon a termination of employment with Good Reason shall be receipt of the Severance
          Benefits and the COBRA Benefits, subject to Executive’s execution and non-revocation of the Release of Claims, and the Accrued Obligations.

     

    (f)          Termination by Executive without Good Reason. Executive may terminate Executive’s employment without Good Reason by providing the Company thirty (30) days’ written notice of such termination.  In the event of a
          termination of employment by Executive under this Section 7(f), Executive shall be entitled only to the Accrued Obligations.  In the event of a termination of Executive’s employment under this Section 7(f), the Company may, in its sole and
          absolute discretion, by written notice, accelerate the Date of Termination without changing the characterization of such termination as a termination by Executive without Good Reason (and no severance pay, notice pay or pay in lieu of notice or
          similar pay shall be owed to Executive).  Following such termination of Executive’s employment by Executive without Good Reason, Executive shall have no further rights to or interest in any compensation or any other benefits under this
          Agreement.  For the avoidance of doubt, Executive’s sole and exclusive remedy upon a termination of employment by Executive without Good Reason shall be receipt of the Accrued Obligations.

     

    (g)         Release of Claims. Notwithstanding any provision herein to the contrary, the provision of severance benefits pursuant to subsections (d), (e) or (g) of this Section 7 (other than the Accrued Obligations) shall be
          conditioned upon Executive’s execution, delivery to the Company, and non-revocation of the Release of Claims (and the expiration of any revocation period contained in such Release of Claims), such that the Release of Claims becomes effective,
          with all revocation periods having expired unexercised, within sixty (60) days after the Date of Termination.  If Executive fails to execute the Release of Claims in such a timely manner, or timely revokes Executive’s execution of the Release of
          Claims following its execution, Executive shall not be entitled to any of the severance benefits under Sections 7(d) 7(e), or 7(g) (other than the Accrued Obligations).  Notwithstanding the foregoing, if such sixty (60) day period ends in a
          calendar year after the calendar year in which Executive’s employment terminates, then, to the extent required by Section 409A of the Code, any payment of any amount or provision of any benefit under Sections 7(d), 7(e), or 7(g) or otherwise that
          would have been made during the calendar year in which Executive’s employment terminates shall instead be withheld and paid on the first payroll date in the calendar year after the calendar year in which Executive’s employment terminates, after
          which any remaining severance benefits shall thereafter be provided to Executive according to the applicable schedule set forth herein as if no such delay had occurred.

     

    
      6

      
        

    

    Section 8.          Confidentiality and Invention Assignment Agreement; Cooperation.

     

    (a)          Confidentiality and Invention Assignment Agreement. As a condition to Executive’s employment with the Company, Executive is entering into the Confidentiality and Invention Assignment Agreement.  The terms and conditions
          of the Confidentiality and Invention Assignment Agreement are incorporated herein by reference and the obligations and responsibilities set forth therein shall survive the termination of Executive’s employment regardless of the reason for the
          termination.

     

    (b)          Litigation and Regulatory Cooperation. During and after Executive’s employment, Executive shall cooperate fully with the Company in the defense or prosecution of any claims or actions now in existence or which may be
          brought in the future against or on behalf of the Company or any of its subsidiaries which relate to events or occurrences that transpired while the Company employed Executive, provided
            that the Executive will not have an obligation under this paragraph with respect to any claim in which the Executive has filed directly against the Company or related persons or entities or the Company has filed directly against
          Executive.  The Executive’s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company
          or any of its subsidiaries at mutually convenient times.  During and after Executive’s employment, Executive also shall cooperate fully with the Company and its subsidiaries in connection with any investigation or review of any federal, state or
          local regulatory authority as any such investigation or review relates to events or occurrences that transpired while Executive was employed by the Company, provided that
          Executive will not have any obligation under this paragraph with respect to any claim in which Executive has filed directly against the Company or related persons or entities or the Company has filed directly against Executive.  The Company shall
          reimburse Executive for any reasonable out-of-pocket expenses incurred by Executive in connection with Executive’s performance of Executive’s obligations pursuant to this Section 8(b).

     

    Section 9.          Section 409A.

     

    This Agreement is intended to comply with, or be exempt from, Code Section 409A (to the extent applicable) and the parties hereto agree to interpret
      this Agreement in the least restrictive manner consistent therewith.  Without limiting the generality of the foregoing, severance pay pursuant to Sections 7(d), 7(e), or 7(g) constitute separate payments for purposes of Section 1.409A-2(b)(2) of the
      Treasury Regulations and thus, to the extent of payments made from the date of termination of Executive’s employment through March 15 of the calendar year following such termination, such payments are intended to constitute “short-term deferral”
      under Section 1.409A-1(b)(4) of the Treasury Regulations.  To the extent that severance payments or benefits are made following said March 15, they are intended to be payable upon an “involuntary separation from service” pursuant to Section
      1.409A-1(b)(9)(iii) of the Treasury Regulations, to the maximum extent permitted by said provision.  Notwithstanding any other provisions of this Agreement to the contrary, if Executive is a “specified employee” within the meaning of Code Section
      409A and the regulations issued thereunder, and a payment or benefit provided for in this Agreement or otherwise would be subject to additional tax under Code Section 409A if such payment or benefit is paid within six (6) months after Executive’s
      “separation from service” (within the meaning of Code Section 409A), then such payment or benefit shall not be paid (or commence) during the six-month period immediately following Executive’s separation from service except as provided in the
      immediately following sentence.  In such an event, any payments or benefits that would otherwise have been made or provided during such six-month period and which would have incurred such additional tax under Code Section 409A shall instead be paid
      to Executive in a lump-sum cash payment on the earlier of (i) the first regular payroll date of the seventh month following Executive’s separation from service or (ii) the 10th business day following Executive’s death (but not earlier than such
      payments otherwise would have been made).  In addition, no reimbursement or in-kind benefit shall be subject to liquidation or exchange for another benefit and the amount available for reimbursement, or in-kind benefits provided, during any calendar
      year shall not affect the amount available for reimbursement, or in-kind benefits to be provided, in a subsequent calendar year.  Any reimbursement to which Executive is entitled hereunder shall be made no later than the last day of the calendar year
      following the calendar year in which such expenses were incurred.  Notwithstanding anything herein to the contrary, neither the Company nor any of its affiliates shall have any liability to Executive or to any other person or entity if the payments
      and benefits provided in this Agreement that are intended to be exempt from or compliant with Code Section 409A are not so exempt or compliant.

     

    
      7

      
        

    

    Section 10.        Parachute Payment.

     

    In the event that (i) Executive becomes entitled to any payments or benefits hereunder or otherwise from the Company or any of its affiliates which
      constitute a “parachute payment” as defined in Code Section 280G (the “Total Payments”) and (ii) Executive is subject to an excise tax imposed under Code Section 4999
      (the “Excise Tax”), then, if it would be economically advantageous for Executive, the Total Payments shall be reduced by an amount (including
      zero) that results in the receipt by Executive on an after tax basis (including the applicable federal, state and local income taxes, and the Excise Tax) of the greatest Total Payments, notwithstanding that some or all of the portion of the Total
      Payments may be subject to the Excise Tax.  Any such reduction in payments and benefits shall be applied first against the latest scheduled cash payments; then current cash payments; then any equity or equity derivatives that
      are included under Code Section 280G at full value rather than accelerated value with the highest value reduced first; then other non-cash or non-equity based benefits will be reduced (in the order of latest scheduled payments and benefits to
      earliest scheduled payments); and finally, any equity or equity derivatives included under Code Section 280G at an accelerated value (and not at full value) shall be reduced with the highest value reduced first (as such values are determined under
      Treasury Regulation Section 1.280G-1, Q&A 24).  All calculations hereunder shall be performed by a nationally recognized independent accounting firm selected by the Company, with the full cost of such firm being borne by the Company.  Any
      determinations made by such firm shall be final and binding on Executive and the Company.

     

    Section 11.        Clawback.

     

    Notwithstanding anything herein to the contrary, any equity-based or incentive compensation provided to Executive, including any bonuses or equity
      awards provided pursuant to Sections 4(b) or 4(c) of this Agreement, shall be subject to any “clawback” required by law or by any national securities exchange on which the Company’s securities are listed, or to any clawback or recoupment policy
      otherwise adopted by the Company from time to time.  For the avoidance of doubt, notwithstanding anything herein to the contrary, in no event shall any reduction in the amount of compensation ultimately provided to or retained by Executive on account
      of this Section 11 constitute an event pursuant to which Executive may terminate employment for Good Reason or otherwise constitute a breach of this Agreement by the Company.

     

    Section 12.        No Conflict with Existing Obligations.

     

    Executive represents that Executive’s performance of all the terms of this Agreement and Executive’s duties as an executive of the Company do not and
      will not breach any agreement or obligation of any kind made prior to Executive’s employment by the Company, including agreements or obligations Executive may have with prior employers or entities for which Executive has provided services.  Executive
      has not entered into, and Executive agrees that Executive will not enter into, any agreement or obligation, either written or oral, in conflict herewith.

     

    
      8

      
        

    

    Section 13.        Assignment.

     

    This Agreement for personal services shall not be assigned by Executive.  This Agreement is assignable by the Company and will be binding upon and
      inure to the benefit of any successor or assign of the Company (and by Executive’s signature below, Executive consents to any such assignment).  Any such successor of the Company will be deemed substituted for the Company under the terms of this
      Agreement for all purposes.  For this purpose, “successor” means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the
      assets or business of the Company.

     

    Section 14.        Arbitration; WAIVER OF JURY TRIAL.

     

    Section 15.          In consideration of
          Executive’s employment with the Company, the Company and Executive agree that any and all controversies, claims, or disputes with anyone (including the Company, Executive and any executive, officer, director, shareholder or benefit plan of the
          Company in their capacity as such or otherwise) arising out of, relating to, or resulting from Executive’s employment with the Company or the termination of Executive’s employment with the Company, including any relating to this Agreement, will
          be subject to binding arbitration.  Disputes which Executive and Company hereby agree to arbitrate, AND THEREBY AGREE TO WAIVE ANY RIGHT TO A TRIAL BY JURY, include,
          but are not limited to, any statutory claims under state or federal law, including, but not limited to, claims under Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act of 1990, the Age Discrimination in Employment Act
          of 1967, the Older Workers Benefit Protection Act, the Worker Adjustment and Retraining Notification Act, the Family and Medical Leave Act, the New Jersey Law Against Discrimination, the New Jersey Conscientious Executive Protection Act, the New
          Jersey Family Leave Act, and any other federal, state or local discrimination, retaliation or wrongful termination claims or other statutory or common law claims.  Executive further understands that this agreement to arbitrate also applies to any
          disputes that the Company may have with Executive.  Executive and Company agree that any arbitration will be administered by the American Arbitration Association (“AAA”) and that a single neutral arbitrator will be selected in a manner consistent
          with its National Rules for the Resolution of Employment Disputes (the “Rules”), which are available on AAA’s website at https://www.adr.org/Rules.  All arbitration fees and costs shall
          be paid by the Company (except that if Executive initiates such arbitration, Executive shall be responsible for covering a portion of such costs equivalent to the filing fees Executive would have incurred had Executive asserted such claim in a
          court of competent jurisdiction), but the parties shall be responsible for payment of their own attorneys’ and professional fees.  Executive and Company agree that the arbitrator will administer and conduct any arbitration in a manner consistent
          with the Rules.  Notwithstanding the foregoing, nothing herein shall limit or alter the Company’s right to seek injunctive or other equitable relief in any court of competent jurisdiction under (and as described in) the Confidentiality and
          Invention Assignment Agreement.  Additionally, (i) nothing in this Section 15 shall prevent Employee from filing a complaint or charge with the National Labor Relations Board (NLRB), the Equal Employment Opportunity Commission (EEOC), New Jersey
          Division on Civil Rights (NJDCR), or any similar federal or state administrative agency, including claims for workers’ compensation or unemployment insurance benefits, and (ii) notwithstanding anything to the contrary herein, the agreement to
          arbitrate under this Section 15 does not cover: (A) claims for workers’ compensation benefits; (B) claims for unemployment compensation benefits; or (C) claims for sexual harassment or abuse or claims of discrimination that are based on the same
          facts and circumstances or otherwise related to excluded sexual harassment and abuse claims if any applicable federal, state, or local law prohibits mandatory arbitration of those claims.  By their initials below, the Company and Executive
          acknowledge and agree that they have read and are agreeing to the terms of this Section 15:

     

    	
            Company Initials:

          	FBA

          	 	
            Executive Initials:

          	MH

          	 

    

    

    
      9

      
        

    

    Section 16.        Voluntary Nature of Agreement.

     

    Executive acknowledges and agrees that Executive is executing this Agreement voluntarily and without any duress or undue
      influence by the Company or anyone else.  Executive further acknowledges and agrees that Executive has carefully read this Agreement and that Executive has asked any questions needed for Executive to understand the terms, consequences and binding
      effect of this Agreement and fully understands it.  Finally, Executive agrees that Executive has been provided an opportunity to seek the advice of an attorney of Executive’s choice before signing this Agreement.

     

    Section 17.        Other.

     

    (a)        Waiver of Breach. The waiver by the Company of a breach by Executive of any provision of this Agreement or the Confidentiality and Invention Assignment Agreement shall not operate or be construed as a waiver of the
          Company’s rights with respect to any subsequent breach by the Executive.  Any waiver of any provision of this Agreement must be in writing and signed by the waiving party.

     

    (b)          Governing Law. This Agreement shall be construed and administered in accordance with the laws of the State of New Jersey, exclusive of its conflict of laws rules, and the parties hereto agree and stipulate that
          this Agreement shall be deemed to have been entered into in the State of New Jersey, regardless of where it was negotiated, implemented and/or executed.

     

    (c)          Severability. In the event that any one or more of the provisions of this Agreement shall for any reason be held to be invalid, illegal, or unenforceable, the remaining provisions of this Agreement shall be unimpaired,
          and shall continue in full force and effect.

     

    (d)        Construction. This Agreement shall be interpreted in accordance with its plain meaning, and the rule that ambiguities shall be construed against the drafter of the document shall not apply in connection with the
          construction or interpretation hereof.

     

    (e)          Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

     

    (f)          Entire Agreement. This Agreement and the Confidentiality and Invention Assignment Agreement contain the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersede all prior
          or contemporaneous promises, understandings, or agreements, whether written or oral, relating to the subject matter hereof.  This Agreement may not be changed orally, but only by an agreement in writing, signed by both
          parties.

     

    (g)          Survivorship.  The provisions of Sections 1, 7(d), 7(e), 7(g) and   Sections 8 through 16 shall survive the termination of Executive’s employment with the Company and this Agreement.

     

    [Signature Page Follows]

     

    
      10

      
        

    

    
    IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year
      first above written.

     

    	 	
            PDS BIOTECHNOLOGY CORPORATION

          
	 	 
	
            Date:  October 4, 2021

          	
            /s/ Frank Bedu-Addo, PhD

          
	 	 
	 	
            By:

          	
            Frank Bedu-Addo, PhD

          
	 	
            Title:

          	
            President and Chief Executive Officer

          
	 	 	 
	 	
            EXECUTIVE

          
	 	 	 
	
            Date:  October 4, 2021

          	
            /s/ Matthew Hill

          
	 	 
	 	
            Matthew Hill

          

    

    

    
      11

      
        

    

    
      Exhibit A

      

      

      EMPLOYEE CONFIDENTIALITY AND INVENTION ASSIGNMENT AGREEMENT

      

      

      [***]

       

        

    

    
      12

      
        

    

    
      Exhibit B

      

      

      [***]

    

    

    

    

    

    13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]